Accession PRJCA002282
Title Circulating tumor DNA is capable of monitoring the therapeutic response and resistance in advanced colorectal cancer patients undergoing combined target and chemotherapy
Relevance Medical
Data types Raw sequence reads
Genome sequencing
Organisms Homo sapiens
Description Colorectal cancer (CRC) is a highly lethal disease worldwide. The majority of patients receiving targeted therapy or chemotherapy develop drug resistance, while its molecular mechanism remains to be elucidated. The plasma circulating tumor DNA (ctDNA) exhibited the potential in identifying gene variations and monitoring drug resistance in CRC treatment. In this study, we monitored the ctDNA mutational changes in advanced CRC patients underwent first-line therapy with bevacizumab and cetuximab combined with chemotherapy. The dynamic change of plasma mutation status was consistent with the tissue tumor burden and was closely correlated with disease progression. In conclusion, ctDNA monitoring is a useful method for molecular genotyping of colorectal cancer patients. Dynamic changes in resistance can be sensitively monitored by gene variation status, which potentially helps to develop treatment strategy.
Sample scope Multiisolate
Release date 2020-02-26
Grants
Agency program Grant ID Grant title
Sanming project of Shenzhen People Hospital SYLY201725
Submitter lele    song  (songlele@sina.com)
Organization HaploX Biotechnology Co., Ltd
Submission date 2020-02-26

Project Data

Resource name Description